| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f9bfd5bc7d4af1f512164c65ba97db2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J1-00 |
| filingDate |
1993-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c89595d2ae67da198356383f327b6a56 |
| publicationDate |
1996-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0746322-A1 |
| titleOfInvention |
Treatment of alzheimer's disease and modulation of immune system with delta5-androstenes |
| abstract |
Alzheimer's disease and immune deficiency disorders may be effectively treated by administering a therapeutic amount of a Δ5-Androstene-3β-ol-17-one having a C7 substituent selected from the group consisting of oxo, hydroxy and groups convertible thereto by hydrolysis. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10342805-B2 |
| priorityDate |
1992-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |